Scientists at The Wistar Institute have solved a longstanding puzzle in ovarian cancer treatment: why anti-estrogen therapy often fails even when tumors express the hormone receptor that should make ...
Postmenopausal patients with ovarian or endometrial cancer who received conjugated equine estrogen may have increased mortality rates. For patients with ovarian and endometrial cancer, receiving ...
CHICAGO — Cancer risk among women varied based on the type of menopausal hormone therapy they used, according to randomized study results scheduled for presentation at ASCO Annual Meeting. Perspective ...
An open, prospective, single arm, phase II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) with neoadjuvant chemotherapy in patients with advanced ovarian cancer: Interim analysis from the ...
The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...
The first drug for a rare and difficult-to-treat type of ovarian cancer has been granted accelerated approval by the Food and Drug Administration (FDA). The treatment, called avutometinib plus ...
However, conjugated equine estrogen plus medroxyprogesterone acetate does not increase this risk and may cut risk for developing uterine cancer. HealthDay News — Conjugated equine estrogen (CEE) taken ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback